J&J Turns to Network Inference and Pathway Informatics for Cancer Biomarker Discovery | GenomeWeb

Computational systems biology is giving oncology research a boost at Johnson & Johnson Pharmaceutical Research and Development, where scientists are using technology from Gene Network Sciences, Ariadne Genomics, and GeneGo to elucidate the mechanism of action of potential therapeutics and point the way toward biomarkers related to drug efficacy and response.

Timothy Perera, a principal scientist in the oncology research early development group at J&J PRD Europe, presented early results of this work at the annual Cancer Progress conference in New York on March 8.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.